diagnostic value comparative analysis of the commercial kits for the detection of sars-cov-2 in clinical samples: a systematic review and meta-analysis

Background and objectives: rapid and accurate identification of suspicious sars-cov-2 patients is essential in controlling the infection. numerous commercial kits are developed which target diverse regions of the sars-cov-2 virus genome. this systematic review addresses the lack of comprehensive analyses comparing the diagnostic value of commercial kits for sars-cov-2 detection. we aimed to compare diagnostic value of commercial sars-cov-2 kits in clinical samples using a systematic review and meta-analysis method.materials and methods: a comprehensive search was conducted on main databases of medline (pubmed), embase, web of science and scopus from 2019 to october 2021 using the appropriate keywords. systematic reviews and meta-analysis guideline prisma checklist was used to select eligible studies.results: the most frequent introduced kits were from usa (33 cases) and china (27). among all studies, 11, 9 and 7 papers had assessed fda –cdc, sansure and allplex kits, respectively. the majority of the kits were based on rt-pcr (52 cases) and the most frequent genes target was n protein (63 cases). the overall sensitivity of the kits was 80.5%. the lowest sensitivity was reported for daan kit, while the highest sensitivity was seen for many kits. the specificity of the kits ranged from 87.9% to 99.8% and the overall specificity was 97.9%. both ppv and npv of the kits ranged from 87.9% to 99.8% for ppv and 82.9% to 99.8% for npv.conclusion: based on dor obtained from three different formulas, genefinder, inbios, nxtag, simplexa and fda-cdc kit have better detection performance. the genefinder kit appears to be among the more suitable options regarding cost-effectiveness for each reaction.